Inflammatory Myopathies in Children

Rheumatic Disease Clinics of North America

Volumn 33, Issue 3, 2007, Pages 525-553

  Compeyrot Lacassagne, Sandrine ^a   Feldman, Brian M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CELL ADHESION MOLECULE; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN CLASS 1; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; TACROLIMUS;

ADOLESCENT; AUTOIMMUNE DISEASE; CALCINOSIS; CAPILLAROSCOPY; CASE REPORT; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; ELECTROMYOGRAPHY; ENVIRONMENTAL FACTOR; EYE DISEASE; FACE RASH; FEMALE; GENETIC DISORDER; GENETIC PREDISPOSITION; HEART DISEASE; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; LABORATORY DIAGNOSIS; LIPODYSTROPHY; LUNG DISEASE; METABOLIC DISORDER; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; MYOTONIA; NEUROMUSCULAR DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS;

EID: 34948850874     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.07.002     Document Type: Review

References (98)

1. Bohan A., and Peter J.B. Polymyositis and dermatomyositis. [part 1 of 2]. N Engl J Med 292 7 (1975) 34-37
2. Banker B.Q., and Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 45 4 (1966) 261-289
3. Symmons D.P.M., Sills J.A., and Davis S.M. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34 (1995) 732-736
4. Mendez E.P., Lipton R., Ramsey-Goldman R., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49 3 (2003) 300-305
5. Medsger T.A.J., Dawson W.N., and Masi A.T. The epidemiology of polymyositis. Am J Med 48 (1970) 715-723
6. Ang P., Sugeng M.W., and Chua S.H. Classical and amyopathic dermatomyositis seen at the national centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 29 2 (2000) 219-223
7. Pachman L.M. Juvenile dermatomyositis: immunogenetics, pathophysiology and disease expression. Rheum Dis Clin North Am 28 (2002) 579-602
8. Cassidy JT, Petty RE, editors. Juvenile dermatomyositis. In: Textbook of pediatric rheumatology. 4th edition. Philadelphia: WB Saunders; 2001. p. 465-504.
9. *0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol 44 (1995) 131-135
10. Shamim E.A., Rider L.G., and Miller F.W. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 12 (2000) 482-491
11. West J.E., and Reed A.M. Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. Hum Immunol 60 (1999) 255-258
12. Artlett C.M., Ramos R., Jiminez S.A., et al. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 356 9248 (2000) 2155-2156
13. Artlett C.M., Miller F.W., and Rider L.G. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 11 (2001) 1279-1284
14. Reed A.M., Picornell Y.J., Harwood A., et al. Chimerism in children with juvenile dermatomyositis. Lancet 356 (2000) 2156-2157
15. Reed A.M., McNallan K., Wettstein P., et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis. J Immunol 172 (2004) 5041-5046
16. Artlett C.M., O'Hanlon T.P., Lopez A.M., et al. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum 48 9 (2003) 2567-2572
17. Verweij C.L., and Huizinga T.W.J. Tumor necrosis factor alpha gene polymorphisms and rheumatic diseases. Br J Rheumatol 37 (1998) 923-929
18. Wilson A.G., de Vries N., Pociot F., et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177 (1993) 557-560
19. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 94 (1997) 3195-3199
20. Pachman L.M., Liotta-Davis M.R., Hong D.K., et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43 10 (2000) 2368-2377
21. Fedczyna T.O., Lutz J., and Pachman L.M. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol 100 2 (2001) 236-239
22. Lutz J., Huwiler K.G., Fedczyna T., et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol 103 (2002) 260-263
23. Rider L.G., and Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 23 3 (1997) 619-655
24. Massa M., Costouros N., Mazzoli F., et al. Self epitopes shared between human myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 46 11 (2002) 3015-3025
25. *0501 + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 168 8 (2002) 4154-4163
26. Wargula J.C. Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. Curr Opin Rheumatol 15 5 (2003) 595-601
27. Goncalves F.G.P., Chimelli L., Sallum M.E., et al. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 29 (2002) 1301-1307
28. Sallum A.M., Marie S.K., Wakamatsu A., et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 31 4 (2004) 801-807
29. Li C.K.C., Varsani H., Holton J.L., et al. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 31 3 (2004) 605-609
30. Bohan A., and Peter J.B. Polymyositis and dermatomyositis. [part 2 of 2]. N Engl J Med 292 8 (1975) 403-407
31. Feldman B.M., Reichlin M., Laxer R.M., et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 23 10 (1996) 1794-1797
32. Kimball A.B., Summers R.M., Turner M., et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Arthritis Rheum 43 8 (2000) 1866-1873
33. Maillard S.M., Jones R., Owens C., et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 43 5 (2004) 603-608
34. Pachman L.M., Hayford J.R., Chung A., et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25 6 (1998) 1198-1204
35. Pachman L.M. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 42 5 (1995) 1071-1098
36. Miller L.C., Michael A.F., and Kim Y. Childhood dermatomyositis: clinical course and long-term follow-up. Clin Pediatr 26 (1987) 561-566
37. Tse S., Lubelsky S., Gordon M., et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol 28 1 (2001) 192-197
38. Hollister J.R. The evolution of juvenile dermatomyositis into chronic arthritis. Arthritis Rheum 41 Suppl (1998) S203
39. Ramanan A.V., and Feldman B.M. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28 4 (2002) 833-857
40. Peloro T.M., Miller O.F., Hahn T.F., et al. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol 45 1 (2001) 28-34
41. Santmyire-Rosenberger B., and Dugan E.M. Skin involvement in dermatomyositis. Curr Opin Rheumatol 15 6 (2003) 714-722
42. Ghali F.E., Stein L.D., Fine J., et al. Gingival telangiectases. An underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135 (1999) 1370-1374
43. Feldman B.M., Rider L.G., Dugan L., et al. Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies (JIIM). Arthritis Rheum 42 9 (1999) S181
44. Smith R.L., Sundberg J., Shamiyah E., et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 31 8 (2004) 1644-1649
45. Ramanan A.V., and Feldman B.M. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14 6 (2002) 658-662
46. Eddy M.C., Leelawattana R., McAlister W.H., et al. Calcinosis universalis complicating juvenile dermatomyositis: resolution during Probenecid therapy. J Clin Endocrinol Metab 82 11 (1997) 3536-3542
47. Ansell B.M. Juvenile dermatomyositis. Rheum Dis Clin North Am 17 (1991) 931-942
48. Pachman L.M., Callen A.M., Hayford J., et al. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone (IV pulse). Arthritis Rheum 37 Suppl 9 (1994) S429
49. Fisler R.E., Liang M.G., Fuhlbrigge R.C., et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47 (2002) 505-511
50. Bowyer S.L., Blane C.E., Sullivan D.B., et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103 (1983) 882-888
51. Huemer C., Kitson H., Malleson P.N., et al. Lipodystrophy in patients with juvenile dermatomyositis-evaluation of clinical and metabolic abnormalities. J Rheumatol 28 3 (2001) 610-615
52. Senior B., and Gellis S.S. The syndromes of total lipodystrophy and partial lipodystrophy. Pediatrics 33 (1964) 593-612
53. Trapani S., Camiciottoli G., Vierucci A., et al. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatol 40 (2001) 216-220
54. Pachman L.M., and Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr 96 2 (1980) 226-234
55. Rider L.G., Miller F.W., and Targoff I.N. Myositis specific autoantibodies (MSA) in children: a broadened spectrum of juvenile myositis. Arthritis Rheum 36 (1993) S258
56. Fortenberry J.D., and Shew M.L. Fatal Pneumocystis carinii in an adolescent with systemic lupus erythematosus. J Adolesc Health Care 10 6 (1989) 570-572
57. Elst E.F., Kamphuis S.S.M., Prakken B.J., et al. Severe central nervous system involvement in juvenile dermatomyositis. J Rheumatol 30 9 (2003) 2059-2063
58. Ramanan A.V., Sawhney S., and Murray K.J. Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology (Oxford) 40 11 (2001) 1293-1298
59. Regan M., Haque U., Pomper M., et al. Central nervous system vasculitis as a complication of refractory dermatomyositis. J Rheumatol 28 (2001) 207-211
60. Askari A.D., and Huettner T.L. Cardiac abnormalities in polymyositis/dermatomyositis. Semin Arthritis Rheum 12 2 (1982) 208-219
61. Jimenez C., Rowe P.C., and Keene D. Cardiac and central nervous system vasculitis in a child with dermatomyositis. J Child Neurol 9 3 (1994) 297-300
62. Bitnum S., Daeschner C.W.J., and Travis L.B. Dermatomyositis. J Pediatr 64 (1964) 101-131
63. Haupt H.M., and Hutchins G.M. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J Cardiol 50 5 (1982) 998-1006
64. Akikusa J.D., Tennankore D.K., Levin A.V., et al. Eye findings in patients with juvenile dermatomyositis. J Rheumatol 32 10 (2005) 1968-1991
65. Euwer R.L., and Sontheimer R.D. Amyopathic dermatomyositis: a review. J Invest Dermatol 100 1 (1993) 124S-127S
66. Plamondon S., and Dent P.B. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 27 8 (2000) 2031-2034
67. El-Azhary R.A., and Pakzad S.Y. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46 4 (2002) 560-565
68. Huber A.M., Feldman B.M., Rennebohm R.M., et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50 5 (2004) 1595-1603
69. Singh G., Athreya B.H., Fries J.F., and Goldsmith D.P. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 37 (1994) 1761-1769
70. Feldman B.M., Ayling-Campos A., Luy L., et al. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 22 2 (1995) 326-331
71. Huber A.M., Hicks J.E., Lachenbruch P.A., et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 28 5 (2001) 1106-1111
72. Lovell D.J., Lindsley C.B., Rennebohm R.M., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 42 10 (1999) 2213-2219
73. Rennebohm R.M., Jones K., Huber A.M., et al. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 51 3 (2004) 365-370
74. Ruperto N., Ravelli A., Murray K.J., et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatol 42 (2003) 1452-1459
75. Isenberg D.A., Allen E., Farewell V., et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial indices in patients with adult onset disease. Rheumatol 43 (2004) 49-54
76. Miller F.W., Rider L.G., Chung Y.L., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 11 (2001) 1262-1273
77. Laxer R.M., Stein L.D., and Petty R.E. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 30 3 (1987) 328-334
78. Paller A.S. The use of pulse corticosteroid therapy for juvenile dermatomyositis. Pediatr Dermatol 13 4 (1996) 347-348
79. Klein-Gitelman M.S., Waters T., and Pachman L.M. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 13 6 (2000) 360-368
80. Klein-Gitelman M.S., and Pachman L.M. Intravenous corticosteroids (IV CS): adverse reactions are more variable than expected in children. J Rheumatol 25 (1998) 1995-2002
81. Miller L.C., Sisson B.A., Tucker L.B., et al. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 35 10 (1992) 1143-1149
82. Al-Mayouf S., Al-Mazyed A., and Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19 (2000) 138-141
83. Ramanan A, Campbell-Webster N, Tran D, et al. Initial treatment of juvenile dermatomyositis (JDM) using methotrexate (MTX) and aggressively tapered prednisone (PRED). Pediatric Rheumatology Online Journal;1(4):120. Available at http://www.pedrheumonlinejournal.org/July/derm/123.htm. Accessed February 8, 2005.
84. Al-Mayouf S.M., Laxer R.M., Schneider R., et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27 10 (2000) 2498-2503
85. Sansome A., and Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases. Arch Dis Child 72 (1995) 25-28
86. Lang B., and Murphy G. Treatment of dermatomyositis with intravenous globulin. Am J Med 91 (1991) 169-172
87. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 27 (1993) 1993-2000
88. Riley P., Maillard S.M., Wedderburn L.R., et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatol 43 4 (2004) 491-496
89. Heckmatt J., Hasson N., Saunders C., et al. Cyclosporin in juvenile dermatomyositis. Lancet (1989) 1063-1066
90. Zeller V., Cohen P., Prieur A., et al. Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 23 8 (1996) 1424-1427
91. Kobayashi I., Yamada M., Takahashi Y., et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 42 2 (2003) 371-374
92. Olson N.Y., and Lindsley C.B. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16 12 (1989) 1545-1547
93. Yoshimasu T., Ohtani T., Sakamoto T., et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12 (2002) 50-52
94. Hollar C.B., and Jorizzo J.L. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 15 1 (2004) 35-39
95. Ueda M., Makinodan R., Matsumura M., et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 148 (2003) 593-611
96. Paller A., Eichenfield L.F., and Leung D.Y.M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44 1 Suppl (2001) S47-S57
97. Shehata R., Al-Mayouf S., Al-Dalaan A., et al. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 17 1 (1999) 115-118
98. Huber A.M., Lang B., LeBlanc C.M.A., et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 3 (2000) 541-549